Summary
A role for serotonin in migraine has been supported by changes in circulating levels of serotonin and its metabolites during the phases of a migraine attack, along with the ability of serotonin-releasing agents to induce migraine-like symptoms. The development of serotonin receptor agonists with efficacy in the clinic for the alleviation of migraine pain further implicates serotonin as a key molecule in migraine.
Several theories regarding the etiology of migraine have been proposed. The vasodilatory theory of migraine suggested that extracranial arterial dilation during an attack was related to migraine pain; a theory supported when vasoconstrictors such as sumatriptan alleviated migraine pain. The neurological theory of migraine proposed that migraine resulted from abnormal firing in brain neurons. Cortical spreading depression, one facet of the neurological theory, could explain the prodrome of migraine. The neurogenic dural inflammation theory of migraine supposed that the dural membrane surrounding the brain became inflamed and hypersensitive due to release of neuropeptides from primary sensory nerve terminals. Substance P, calcitonin gene related peptide and nitric oxide are all though to play a role in the dural inflammatory cascade.
Animal models of migraine have been utilized to study the physiology of migraine and develop new pharmaceutical therapies. One model measures the shunting of blood to arterovenous anastomoses based on a proposal that migraine primarily involves cranial arteriovenous vasodilation. Another model utilizes electrical stimulation of the trigeminal ganglion to indoce neurogenic dural inflammation quantified by the resulting extravasation of proteins. Pharmacological agents such as meta-chlorophenylpiperazine (mCPP) and nitroglycerin have also been used to induce dural extravasation in animals. Both compounds also induce migraine attacks in individuals with a history of migraine. In addition, Fos, a protein produced by activation of the c-fos gene, has been measured as an index of migraine-like pain transmission to the CNS following chemical or electrical stimulation of the trigeminal nerve.
A role for serotonin in migraine is further supported by the efficacy of serotonin receptor ligands. Sumatriptan is an agonist at 5-HT1D and 5-HT1B receptor subtypes, and effective in treating migraine pain and associated symptoms. Recently, selective 5-HT1F agonists have been proposed for the treatment of migraine, without the side effects associated with the present 5-HT1D and 5-HT1B receptor agonists. A role for 5-HT2B receptors has also been suggested in the initiation of migraine, supporting use of selective 5-HT2B receptor antagonists in migraine. Thus, agents that modulate 5-HT1B, 5-HT1D, 5-HT1F and 5-HT2B receptors either have or may have clinical utility in the therapy of migraine headache.
Keywords
- review
- serotonin
- migraine
- animal models
- neurogenic inflammation
- dural protein extravasation
- 5-HT1B receptor, 5-HT1D receptor, 5-HT1F receptor, 5-HT2B receptor
- nitric oxide
- clinical therapies
- serotonin agonists
- serotonin antagonists
- substance P
- calcitonin gene-related peptide
This is a preview of subscription content, access via your institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
Abbreviations
- 5-HIAA:
-
5-hydroxyindole acetic acid
- 5-HT:
-
5-hydroxytryptamine (serotonin)
- CGRP:
-
calcitonin gene-related peptide
- mCPP:
-
meta-chlorophenylpiperazine
- NO:
-
nitric oxide
- CNS:
-
central nervous system
- L-NAME:
-
N-nitro-L-arginine methyl ester
References
Sicuteri F., Testi A. and Anselmi B.: Int. Arch. Allergy 19, 55–58 (1961).
Curran D.A., Hinterberger H. and Lance J.W.: Brain 88, 997–1007 (1965).
Anthony M., Hinterberger H.J. and Lance J.W.: Arch. Neurol. 16, 544–552 (1967).
Ferrari M.D., Odink J., Tapparelli C., Van Kempen G.M.J., Pennings E.S.M. and Bruyn G.W.: Neurology 39, 1239–1242 (1989).
Fozard J.R.: Prog. Pharmacol. 4, 135–146 (1982).
Griffith S.C. and Burnstock G.: Lancet 1, 561–562 (1983).
Carroll J.D. and Hilton B.T.: Headache 14, 149–156 (1974).
Del Bene E., Anselmi B., Del Bianco P.L., Fanciullacci M., Gali P., Salmon S. and Sicuterri F., in: E Sicuteri (ed.): Headache, new vistas. Biomedical Press, Florence 1977, pp. 101–109.
Graham J.R. and Wolff H.G.: Arch. Neurol. Psychia. 39, 737–763 (1938).
Nichols E.T., Mawad M. and Mohr J.P.: Stroke 21, 555–559 (1990).
Dahl A., Russell D., Nyberg-Hansen R. and Rootwelk K.: Cephalalgia 10, 87–94 (1990).
Kimball R., Friedman A. and Vallejo E.: Neurology 10, 107–111 (1960).
Saxena P.R., in: J.N. Blau (ed.): Migraine — therapeutic, conceptual and research aspects. Elsevier, Amsterdam 1987, pp. 581–596.
Saxena P.R., in: J. Olesen and M.A. Moskowitz (eds.): Experimental headache models in animal and man. Lippincott-Raven Publishers, Philadelphia 1995, 189–198.
Andersen A.R., Freiberg L., Olsen T.S. and Olesen J.: Arch. Neurol. 45, 154–159 (1988).
Ferrari M.D., Haan J., Blokland J.A.K., Arndt J.W., Minnee P., Zwinderman A.H., Pauwels E.K.J. and Saxena P.R.: Arch. Neurol. 52, 135–139 (1995).
Zwetsloot C.P., Caekebeke J.F.V. and Jansen J.C.: Cephalalgia 11, 103–107 (1991).
Zwetsloot C.P., Caebeke J.F.V. and Ferrari M.D.: Stroke 24, 1335–1338 (1993).
Olsen J. and Paulson O.B.: Stroke 2, 148–159 (1971).
Wei E.P., Moskowitz M.A., Boccalini P. and Kontos H.A.: Circ. Res. 70, 1313–1319 (1992).
Goadsby P.J. and Edvinsson L.: Ann. Neurol. 33, 48–56 (1993).
Moskowitz M.A.: Trends Pharmacol. Sci. 13, 307–311 (1992).
Pearce J.M.S.: Lancet 2, 86–89 (1984).
Moskowitz M.A., Nozaki K. and Kraig R.P.: J. Neurosci. 13, 1167–1177 (1993).
Moskowitz M.A.: Neurology 43, S 16–20 (1993).
Markowitz S., Saito K. and Moskowitz M.A.: J. Neurosci. 7, 4129–4136 (1987).
Moskowitz M.A.: Neurology 41, 182–186 (1991).
Ray B.S. and Wolff H.G.: Arch. Surg. 41, 813–856 (1940).
Goadsby P.J., Zagami A.S. and Lambert G.A.: Headache 31, 365–371 (1991).
Goadsby P.J., Edvinsson L. and Ekman R.: Ann. Neurol. 23, 193–196 (1988).
Moskowitz M.A., Lee W.S. and Cutrer E.M., in: P. Geppetti and P. Holzer (eds.): Neurogenic Inflammation, CRC Press, New York 1996, 187–199.
Beattie D.T., McNeil D.K. and Connor H.E.: Neuropeptides 213, 228–230 (1993).
Dimitriadou V., Buzzi M.G., Moskowitz M.A. and Theoharides T.C.: Neuroscience 44, 97–112 (1991).
Dimitriadou V., Buzzi M.G., Theoharides T.C. and Moskowitz M.A.: Neuroscience 48, 187–203 (1992).
Brain S.D. and Williams T.J.: Br. J. Pharmacol. 86, 855–860 (1985).
Le Greves P., Nyberg F., Terenius L. and Hokfelt T.: Eur. J. Pharmacol. 115, 309–311 (1985).
Olesen J., Thomsen L.L. and Iversen H.K.: Trends Pharmacol. Sci. 15, 149–153 (1994).
Olesen J., Inversen H.K. and Thomsen L.L.: Neuroreport 4, 1027–1030 (1993).
Thomsen L.L., Kruuse C., Iversen H.K. and Olesen J.: Eur. J. Neurol. 1, 73–80 (1994).
Lassen L.H., Ashina M., Christiansen I., Ulrich F. and Olesen J.: Lancet 349, 401–402 (1997).
Fozard J.R.: Arch. Int. Pharmacodyn. 329, 111–119 (1995).
Jeffrey S.R. and Snyder S.H.: Ann. Rev. Cell Dev Biol. 11, 417–440 (1995).
Schmuck K., Ullmer C., Kalkman H.O., Probst A. and Lubbert H.: Eur. J. Neurosci. 8, 959–967 (1996).
Humphrey P.P., Feniuk W., Perren M.J., Connor H.E., Oxford A.W., Coates L.H. and Butina D.: Br. J. Pharmacol. 94, 1123–1132 (1988).
Humphrey P.P., Feniuk W., Perren M.J., Connor H.E. and Oxford A.W.: Cephalalgia Suppl. 9, 23–33 (1989).
Peroutka S.J. and McCarthy B.G.: Eur. J. Pharmacol. 163, 133–136 (1989).
Humphrey P.P., Feniuk W. and Perren M.J.: Headache 30, 12–16 (1990).
Deliganis A.V. and Peroutka S.J.: Headache 336, 228–231 (1991).
Weinshank R.L., Zgombick J.M., Macchi M.J., Branchek T.A. and Hartig P.R.: Proc. Natl. Acad. Sci. USA 89, 3630–3634 (1992).
Adham N., Kao H.T., Schecter L.E., Bard J., Olsen M., Urquhart D., Durkin M., Hartig R.R., Weinshank R.L. and Branchek T.A.: Proc. Natl. Acad. Sci. USA 90, 408–412 (1993).
Pascual J., Arco C.D., Romon T., Olmo E.D. and Pazos A.: Eur. J. Pharmacol. 295, 271–274 (1996).
Bouchelet I., Cohen Z., Case B., Seguela P. and Hamel E.: Mol. Pharmacol. 50, 219–223 (1996).
Johnson K.W., Schaus J.M., Durkin M.M., Audia J.E., Kaldor S.W., Flaugh M.E., Adham N., Zgombick J.M., Cohen M.L., Branchek T.A. and Phebus L.A.: NeuroReport 8, 2237–2240 (1997).
Cohen M.L., Johnson K.W., Schenck K.W. and Phebus L.A.: Cephalalgia 17, 631–638 (1997).
Willett F., Curven N., Adams J. and Armitage M.: Br. Med. J. 304, 1415 (1992).
Hillis W.S. and Maclntyre P.D.: Lancet 341, 1564–1565 (1993).
Ottervanger J.P., Paalman H.J., Boxma G.L. and Stricker B.H.: Lancet 341, 861–862 (1993).
Kalkman H.O.: Life Sci 54, 641–644 (1994).
Johnson K.W., Nelson D.L., Wainscott D.B., Lucaites V.L. and Phebus L.A.: Cephalalgia 17, 342 (1997).
Meyer J.S., Hata T. and Miai A., in: J.N. Blau (ed.): Migraine-therapeutic, conceptual and research aspects. Elsevier, Amsterdam 1987, pp. 265–302.
Heyck H.: Res. Clin. Stud. Headache 22, 1–28 (1969).
Saxena P.R. and Verdouw P.D.: J. Physiol. (Lond.) 332, 501–520 (1982).
Saxena P.R., DeVries P., Heiligers J.P.C., VanDenBrink A.M., Bax W.A., Barv T. and Wikstrom H.: Eur. J. Pharmacol. 312, 53–62 (1996).
Saxena R.R., VanDenBrink A.M., Heiligers J.P.C., Scalbert E. and Lemaitre B.G.: Pharmacol. & Toxicol. 79, 199–204 (1996).
Saxena P.R., DeBriew P., Wang W., Heiligers J.P.C., VanDenBrink A.M., Bax W.A. and Yocca F.D.: Naunyn Schmiedeberg’s Arch. Pharmacol. 355, 295–302 (1997).
Perren M.J., Feniuk W. and Humphrey P.P.A.: Cephalalgia 9S, 41–46 (1989).
Buzzi M.G. and Moskowitz M.A.: Br. J. Pharmacol. 99, 202–206 (1990).
Connor H.E., Feniuk W. and Beattie D.T.: Cephalalgia 17, 145–152 (1997).
Martin G.R., Robertson A.D., MacLennan S.J., Prentice D.J., Barrett V.J., Buckingham J., Honey A.C., Giles H. and Moneada S.: Br. J. Pharmacol. 121, 157–164 (1997).
Brewerton T.D., Murphy D.L., Mueller E.A. and Jimmerson D.C.: Clin. Pharmacol. Ther. 43, 605–609 (1988).
Fuller R.W., Kurz K.D., Mason N.R. and Cohen M.L.: Eur. J. Pharmacol. 125, 71–77 (1986).
Nelson D.L., Wainscott D.B., Lucaites V.L., Calligaro D.O., Zgombick J.M., Audia J.E., Phebus L.A., and Johnson K.W.: Cephalalgia 17, 341–342 (1997).
Nozaki K., Boccalini P. and Moskowitz M.A.: Neurosci. 49, 669–680 (1992).
Nozaki K., Moskowitz M.A. and Boccalini P.: Br. J. Pharmacol. 106, 409–415 (1992).
Kaube H., Keay K.A., Hoskin K.L., Bandler R. and Goadsby P.J.: Brain Res. 629, 95–102 (1993).
Shepheard S.L., Williamson D.J., Williams J., Hill R.G. and Hargreaves R.J.: Neuropharmacol. 34, 255–261 (1995).
Buzzi M.G., Sajas D.E. and Moskowitz M.A.: Eur. J. Pharmacol. 165, 251–258 (1989).
Buzzi M.G., Moskowitz M.A., Peroutka S.J. and Byun B.: Br. J. Pharmacol. 103, 1421–1428 (1991).
Curtin T., Brooks A.P. and Roberts J.A.: Br. Med. J. 305, 713–714 (1992).
Luman W. and Gray R.S.: Lancet 341, 1091–1092 (1993).
Cavazos J.E., Caress J.B., Chilukuri V.R., Devlin T., Gray L. and Hurwitz B.J.: Lancet 343, 1105–1106 (1994).
Cady R.K., Wendt J.K., Kirchner J.R., Sargent J.D., Rothrock J.F. and Skaggs H.: JAMA 165, 2831–2835 (1991).
Tfelt-Hansen P.: Cephalalgia 13, 238–244 (1993).
Dahlof C., in: J. Olese (ed.): Frontiers in Headache Research Vol 6. Headache Treatment Trial Methodology and New Drugs. Lippencott-Raven Publishers, Philadelphia 1997, pp. 243–251.
Bates D., Ashford E., Dawson R., Ensink F.B., Gilhus N.E., Olesen J., Pilgrim A.J. and Shevlin P.: Neurol. 44, 1587–1592 (1994).
Phebus L.A., Johnson K.W., Zgombick J.M., Gilbert P.J., VanBelle K., Mancusco V., Nelson D.L.G., Calligaro D.O., Kiefer A.D., Branchek T.A. and Flaugh M.E.: Life Sci. 61, 2117–2126 (1997).
Yu X.J., Waeber C., Castanon N., Scearce K., Hen R., Macor J.E., Chauveau J. and Moskowitz M.A.: Mol. Pharmacol. 49, 761–765 (1996).
Forbes I.T., Kennet G.A., Gadre A., Ham P., Hayward C., Martin J., Thompson R.T., Wood M., Baxter M.D., Glen G.S., Murphy O.E., Steward B.R. and Blackburn T.P.: J. Med. Chem. 36, 1104 (1993).
Forbes I.T., Ham P., Booth D.H., Martin R.T., Thompson M., Baxter G.S., Blackburn T.P., Glen A., Kennett G.A. and Wood M.D.: J. Med. Chem. 38, 2524–2530 (1995).
Forbes I.T., Jones G.E., Murphy O.E., Holland V. and Baxter G.S.: J. Med. Chem. 38(6), 855–857 (1995).
Bonhaus D.W., Bach C., DeSouza A., Salazar F.H.R., Matsuoka B.D., Zuppan P., Chan H.W. and Eglen R.M.: Br. J. Pharmacol. 115, 622–628 (1995).
Thomas D.R., Baxter G.S., Carey J.E., Gager T.L., Gale D.G., Holland V., Muir A., Wilson S. and Wood M.D.: Br. J. Pharmacol. 117, 137P (1996).
Nozulak J., Kalkman H.O., Floersheim P., Hoyer D., Schoeffler P. and Buerki H.R.: J. Med. Chem. 38, 28–33 (1995).
Cohen M.L., Audia J. and Nelson D.: ID Research Alert-Serotonin 2, 1–5 (1997).
Cohen M.L., Schenck K.W., Mabry T.E., Nelson D.L. and Audia J.E.: J. Serotonin Res. 3, 131–144 (1996).
Leysen J.E., Gommeren W., Heylen L., Luyten W.H.M.L., Van De Weyer I., Vanhoenacker P., Haegeman G., Schotte A., Van Gompel P., Wouters R. and Lesage A.S.: Mol. Pharmacol. 50, 1567–1580 (1996).
Domenech T., Beleta J. and Palacios J.M.: Naunyn Schmiedebergs Arch. Pharmacol. 356, 328–334 (1997).
Wurch T., Cathala C., Palmier C., Valentin J.P., John G.W., Colpaert F.C. and Pauwels P.J.: Neurosci. Res. Comm. 18, 155–162 (1996).
Wurch T., Palmier C., Colpaert F.C. and Pauwels P.J.: J. Neurochem. 68, 410–418 (1997).
Yocca F.D., Buchanan J., Gylys J.A., Hamel E., Iben L.G., Izzarelli D.G., Mahle C.D., Myers R., Noonan J.W., Parker E.M., Williams A.D., Sarbin N., Saxena P., Smith D.W. and Wiener H.L.: Cephalalgia 15, 174 (1995).
Gupta P., Napier C.M., Scatchard J., Shepperson N.B. and Wallis R.: Cephalalgia 17, 413 (1997).
Yocca F.D., Gylys J.A., Smith D.W., Ruediger E., Yevich J.P., Mahle C., Wiener H., Marcus R., Smith J., Saxena P. and Moskowitz M.: Cephalalgia 17, 404 (1997).
The Subcutaneous Sumatriptan International Study Group (1991): N. Engl. J. Med. 325, 316–321.
Fowler P.A., Lacey L.F., Thomas M., Keene O.N., Tanner R.J.N., and Baber N.S.: Eur. Neurol. 31, 291–294 (1991).
Cady R.K., Rubino, J., Crummett D. and Littlejohn III T.W.: Arch. Fam. Med. 3(9), 766–772 (1994).
Sheftell F.D., Weeks R.E., Rapoport A.M., Siegel S., Baskin S. and Arrowsmith F.: Headache 34, 67–72 (1994).
Lloyd K.: Eur. Neurol. 34, 40–43 (1994).
Visser W.H.: 5-HT1 receptor agonists in the acute treatment of migraine. Clinical, epidemiological and pharmacological aspects. Eburon-Delft, Delft 1996.
Ferrari M.D., James M.H., Bates D., Pilgrim A.J., Ashford E.A., Anderson B. and Nappi G.: Cephalalgia 14, 330–338 (1994).
Ferrari M.D., Martin G.R., Earl N.L. and Klein K.B.: Eur. Neurol. 36(Suppl2), 19–23 (1996).
Zagami A.S.: Neurology 48(3), S25–S28 (1997).
Solomon G.D., Cady R.K., Klapper J.A., Earl N.L., Saper J.R. and Ramadan N.M.: Neurology 49(5), 1219–1225 (1997).
Gunasekara N.S. and Wiseman, L.R.: CNS Drugs 8(5), 402–408 (1997).
Gijsman H., Kramer M.S., Sargent J., Tuchman M., Matzura-Wolfe D., Polis A., Teall J., Block G. and Ferrari M.D.: Cephalalgia 17(6), 647–651 (1997).
Sciberras D.G., Polvina W.J., Gertz B.J., Cheng H., Stepanavage M., Wittreich J., Olah T., Edwards M. and Mant T.: Br. J. Clin. Pharamcol. 43, 49–54 (1997).
Visser W.H., Terwindt G.M., Reines S.A., Jiang K., Lines C.R. and Ferrari M.D.: Arch Neurol. 53(11), 1132–1137(1996).
Schoen J.: Curr. Opin. Neurol. 10, 237–243 (1997).
Jackson N.C. for the Eletriptan Steering Committee: Cephalalgia 16, 368 (1996).
Cabarrocas X. and Salva M.: Cephalalgia 17, 421 (1997).
Goldstein J., Schellens R., Diener H.C., Dahlof C., Olesen J., Senard J.M., Steiner T.J. and Simard D., in: J. Olesen, P. Tfelt-Hansen (eds.): Headache treatment, trial methodology and new drugs. Lippincott-Raven Publishers, Philadelphia 1997, pp. 279–285.
Diener H.C., Gendolla A., Juptner M., Kaube H. and Limmroth V: Eur Neurol. 38, 167–174 (1997).
Mathew N.T., in: N.T. Mathew (ed.): Advances in Headache. W.B. Saunders Company, Philadelphia 1997, vol. 15(1), 61–83.
Winner P., Ricalde O., Le Force B., Saper J., and Margul B.: Arch. Neurol. 53, 180–184 (1996).
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1998 Springer Basel AG
About this chapter
Cite this chapter
Johnson, K.W., Phebus, L.A., Cohen, M.L. (1998). Serotonin in migraine: Theories, animal models and emerging therapies. In: Jucker, E. (eds) Progress in Drug Research. Progress in Drug Research, vol 51. Birkhäuser, Basel. https://doi.org/10.1007/978-3-0348-8845-5_6
Download citation
DOI: https://doi.org/10.1007/978-3-0348-8845-5_6
Publisher Name: Birkhäuser, Basel
Print ISBN: 978-3-0348-9798-3
Online ISBN: 978-3-0348-8845-5
eBook Packages: Springer Book Archive